McKinsey & Company describes Industry 4.0 as the next phase in the digitization of the manufacturing sector that is being driven by four disruptions: the astonishing rise in data volumes, computational power and connectivity, especially new low-power wide-area networks; the emergence of analytics and business intelligence capabilities; the new forms of human-machine interaction, such as touch interfaces and augmented reality systems; and the improvements in transferring digital instructions
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
GenapSys Nabs $90M to Commercialize Its Breakthrough Electronic Gene Sequencer
- GenapSys launches first-of-its-kind electronic gene sequencer as well as the completion of a $90M series C funding round led by top biotech investor Foresite Capital. - GenapSys is the first & only to use direct electronic sequencing -- this allows for a simpler workflow, dramatically reduced costs, turnaround time and device size.- The GenapSys Sequencer is exceptionally accurate and 100x smaller and more affordable than current high-throughput sequencers and will significantly expand
Read More
InterSystems, Virtusa Partner to Enhance Patient Data Integration
- InterSystems and Virtusa Corporation partner to enhance the healthcare data integration capabilities of its vLife™ life sciences platform.- The Collaboration will create an advanced platform for healthcare data management, research and analytics.InterSystems, and Virtusa Corporation, a global provider of digital strategy, digital engineering, and IT services and solutions have announced their partnership in an effort to drive positive patient outcomes while reducing cost through improved
Read More
Life Image, Graticule Launches Imaging Dataset In AWS Data Exchange
- Life Image and Graticule announced the availability of GLIMPS (Graticule Life Image Machine Parsed Set) data licensing subscriptions in AWS Data Exchange. - GLIMPS (Graticule Life Image Machine Parsed Set) is a de-identified patient-level data set including a summary of features generated from NLP processing on Life Image data. - The goal of GLIMPS is to provide a cost-effective patient-level snapshot to biopharma data science teams to fuel the necessary discussions about these data, leading
Read More
Five Lessons Learned From Building A CRM for Pharma
We all know the pleasure of interacting with technology that does exactly what it’s designed to do. Whether it’s getting to your destination via Waze, reserving dinner through OpenTable or making an electronic payment through Venmo, applications that work have one important thing in common: they are designed with a purpose and are the true experts in getting exactly that thing done seamlessly.
But professional industry software, especially when it comes to healthcare, is a lot more complex.
Read More
Vermont Health Network Launches Pilot Project to Offer Free Genetic DNA Testing
Key Highlights
LunaPBC announces a partnership allowing patients in Vermont to donate genetic information to medical research via a partnership with the University of Vermont Health Network via Invitae.
Free genetic testing is
now offered to qualifying patients to identify increased risk for certain
diseases. Patients can then consent to securely share their data with
researchers through the LunaDNA platform.
In return, patients
receive shares of ownership in the company, allowing
Read More
Mission Bio Expands Into Single-Cell Multi-Omics With Platform That Detects DNA and Protein from the Same Cell
Key Highlights- Mission Bio expands into single-cell multi-omics with the launch of its new proprietary technology platform. - The Tapestri Platform is the first and only to enable key insights to drive the development of more impactful cancer therapies. Mission Bio, Inc., a South San Francisco, CA-based pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced its expansion into single-cell multi-omics. The company’s proprietary technology, the Tapestri
Read More
Aetion, IBM Watson Health Co-Develop Solution for Conducting Regulatory-Grade RWE Analysis
- IBM Watson Health and Aetion will combine the Aetion Evidence Platform with IBM MarketScan data to provide a turn-key solution for conducting regulatory-grade RWE analysis. - The partnership will satisfy mid-market companies’ demand to streamline the drug R&D process and will allow RWE to play a much greater role in support of companies’ drug portfolios. RWE can enable researchers to supplement clinical trials by optimizing the development of treatments, determining new indications for
Read More
3 Myths About Robotic Process Automation in Healthcare, Debunked
Patients’ wellbeing should be the central focus of healthcare. Unfortunately, this isn’t always the case. Studies show that doctors spend almost half their time on data entry and more than half of their workdays managing records instead of caring for patients. Add this lost time to the fact that healthcare in the United States is already understaffed – averaging 2.5 healthcare practitioners to every 1,000 patients – and it’s easy to see that something’s got to give to bring
Read More
Healx Nabs $56M to Expand AI-Driven Drug Discovery Platform for Rare Diseases
- UK startup Healx lands $56M, led by Atomico to build an AI-driven clinical-stage portfolio for rare diseases, including treatments for fragile X syndrome, the leading genetic cause of autism.
- Healx’s Rare Treatment Accelerator program is a new initiative launched in close partnership with patient communities to identify clinic-ready treatments for rare diseases within 24 months.
Healx, a Cambridge, England-based AI-powered and patient-inspired technology company specializing in
Read More
